Status:

COMPLETED

A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)

Lead Sponsor:

Astellas Gene Therapies

Conditions:

Males With X-linked Myotubular Myopathy (XLMTM)

Eligibility:

MALE

Brief Summary

This retrospective medical chart review (RECENSUS) of approximately 100 XLMTM patients (with a goal to obtain 50 deceased and 20 living records) will provide further knowledge about the clinical manif...

Eligibility Criteria

Inclusion

  • Patient diagnosed with XLMTM resulting from a confirmed mutation in the MTM1 gene, or a combination of XLMTM genetically confirmed family history and muscle biopsy
  • Patient is male
  • Access to available medical records for each patient
  • Signed informed consent by the parent(s) or legal guardians and/or assent by the patient (when applicable), unless the associated IRB provides an appropriate consent waiver

Exclusion

  • Patient data after participation in an interventional study designed to treat XLMTM (patient data prior to participation in an interventional study may be included)

Key Trial Info

Start Date :

September 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2019

Estimated Enrollment :

161 Patients enrolled

Trial Details

Trial ID

NCT02231697

Start Date

September 1 2014

End Date

December 1 2019

Last Update

July 29 2022

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Cure CMD

San Pedro, California, United States, 90732

2

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

3

University of Florida - Gainesville, Children's Research Institute

Gainesville, Florida, United States, 32610

4

Lurie Children's Hospital

Chicago, Illinois, United States, 60611